Patents by Inventor Kenneth J. Clemetson

Kenneth J. Clemetson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
    Patent number: 8198030
    Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPIV can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: June 12, 2012
    Assignee: Aventis Pharma Deutschland, GmbH
    Inventor: Kenneth J. Clemetson
  • Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
    Patent number: 7928066
    Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPIV can be used to monitor platelet age and exposure to thrombiotic and cardiovascular diseases.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: April 19, 2011
    Assignee: Aventis Pharma Deutschland GmbH
    Inventor: Kenneth J. Clemetson